Selective cytotoxic agent drug D for 3D spheroid pancreatic cancer cells
PRUNUS Therapeutics' Drug D is a novel agent showing selective cytotoxicity against pancreatic ductal adenocarcinoma (PDAC) cells in 3D spheroid cultures, offering potential for targeted cancer treatment. Seeking licensing for further development and in vivo validation.
Overview
Drug D, developed by PRUNUS Therapeutics, represents a novel therapeutic approach targeting pancreatic ductal adenocarcinoma (PDAC) cells. It is designed to selectively exert cytotoxic effects on cancer cells that grow in 3D spheroid cultures, a condition that mimics the tumor microenvironment (TME) more accurately than traditional 2D cultures. This selectivity offers significant potential for targeted cancer therapies, particularly for PDAC, which is known for its aggressive nature and resistance to conventional treatments.
Technical specifications
Key features:
- Selective cytotoxicity: Drug D demonstrates a unique ability to kill PDAC cells in 3D spheroid cultures without affecting the same cells in 2D monolayer cultures, indicating a mechanism that targets the 3D tumor architecture.
- Broad applicability: While initially focused on PDAC, the mechanism of Drug D can potentially be applied to other malignant cells capable of forming 3D spheroids, suggesting broader oncological applications.
- Research and validation: Initial in vitro studies have confirmed the efficacy of Drug D against PDAC cells. Future research will include in vivo studies using mouse models and safety assessments necessary for Investigational New Drug (IND) submission.
Technology readiness level
Drug D is currently at Technology Readiness Level 3, having demonstrated proof of concept through in vitro studies. The next steps involve in vivo validation and safety evaluations to advance toward clinical trials.
About PRUNUS Therapeutics
PRUNUS Therapeutics is a Chicagoland-based biotechnology startup founded in 2016 that focuses on developing sustainable cancer therapeutics. Its primary approach involves targeting the biological differences between cancer and normal cells, particularly by focusing on detached cancer cells that exhibit anoikis resistance and anchorage-independent growth. The company’s leading candidate, internally referred to as :D, is a chemo-free agent designed to destroy cells in attachment-free conditions, such as 3D spheroids, without affecting cells in 2D monolayers. Additionally, the company explores Selective Metabolic Labeling, a technology using non-toxic small molecules to label proteins in cancer cells, aiming to overcome limitations of traditional regimens and high-cost biologics.
This development is significant for oncology, as it seeks to provide new, sustainable treatment options that improve patient outcomes and quality of life by minimizing off-target toxicity and the bystander effects often associated with conventional chemotherapy. By addressing fundamental metastatic processes and utilizing a novel mechanism of action, the company intends to offer alternatives for drug-resistant cancers. PRUNUS Therapeutics is currently in the preclinical stage, actively advancing its therapeutic candidates while navigating the inherent challenges of early-stage pharmaceutical research.
delivered to your inbox.